Skip To Main Content
This platform is for Australian healthcare professionals only
Campus Australia
Campus Australia
View Full Results

ADVENT Dermatology

ADVENT is a medical education programme designed to disseminate knowledge about the role of type 2 inflammation in dermatology

ADVENT is developed in collaboration with an expert steering committee and links the latest science of type 2 inflammation with the clinical management of patients with type 2 diseases, such as atopic dermatitis.

ADVENT dermatology steering committee

Prof Connie Katelaris

Head of Unit, Immunology and Allergy Campbelltown Hospital and Professor of Immunology & Allergy, Western Sydney University

A/Prof Peter Foley

Director of Research at the Skin Health Institute and the Head of Dermatology Research at St Vincent’s Hospital Melbourne.

Dr Li-Chuen Wong

Paediatric and Adult Dermatologist, Sydney Skin and the Head of Dermatology, Children’s Hospital, Westmead.

Dr Diana Rubel

Consultant dermatologist in private practice at Woden Dermatology, Canberra, and a visiting medical officer and Senior Lecturer at The Canberra Hospital and Australian National University.

View the latest Interactive Clinical Tutorial on-demand

Recorded on: Thursday 18 May 2023

Beyond the skin:
Managing eye disorders in severe atopic dermatitis

The first four videos below feature Drs John Hogden and Yves Kerdraon, discussing the management of ocular surface disorders in patients with atopic dermatitis, before commencing and during dupilumab treatment using an evidence based, practical decision framework utilising current data, case studies and expert opinion [1].

The final two videos show Prof Connie Katelaris and A/Prof Peter Foley joining Dr Li-Cheun Wong (Chair) and ophthalmology experts (Drs Hogden and Kerdraon) for Q&A panel discussions.

  1. Foley P, et al. Australas J Dermatol. 2022, 63(4):421-436.

Ocular surface disorders (OSD) associated with atopic dermatitis (AD)

Dr Hogden discusses the occurrence and management  of OSD in patients with severe AD

Dupilumab-associated ocular surface disorder (DAOSD)

Dr Kerdroan presents a practical decision framework supporting management of DAOSD

Case study: Managing an atopic dermatitis (AD) patient presenting with an existing ocular surface disorder (OSD)

Dr Hogden presents a case study of a patient with severe AD and existing OSD

Case study: managing dupilumab-associated ocular surface disorder (DAOSD)

Dr Kerdraon presents a case study of a patient with severe AD and DAOSD

Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts

At ADVENTprogram.com you can:

  • Access medical education resources

  • Review the latest science for Type 2 inflammatory diseases
  • Explore your specific interests – select materials by category or topic

Login to ADVENTprogram.com

Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.

Dupixent (dupilumab) PBS Information: Authority Required.

Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with chronic severe atopic dermatitis and uncontrolled severe asthma. This product is not listed on the PBS for children 6 to 11 years of age with severe atopic dermatitis or moderate to severe asthma, or for patients with uncontrolled chronic rhinosinusitis with nasal polyps.

Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

MAT-AU-2300899(v4.0)  |  June 2023